Nonlinear distance measures under the framework of Pythagorean fuzzy sets with applications in problems of pattern recognition, medical diagnosis, and COVID-19 medicine selection

Dutta, Palash; Borah, Gourangajit; Gohain, Brindaban; Chutia, Rituparna

doi:10.1186/s43088-023-00375-8

Beni-Suef University Journal of Basic and Applied Sciences

Table 6 Determination of the best medicine for the treatment of COVID-19

From: Nonlinear distance measures under the framework of Pythagorean fuzzy sets with applications in problems of pattern recognition, medical diagnosis, and COVID-19 medicine selection

Distance measures	Distance values between						Best medicine
Distance measures	\(\left( {M_{1} ,M^{*} } \right)\)	\(\left( {M_{2} ,M^{*} } \right)\)	\(\left( {M_{3} ,M^{*} } \right)\)	\(\left( {M_{4} ,M^{*} } \right)\)	\(\left( {M_{5} ,M^{*} } \right)\)	\(\left( {M_{6} ,M^{*} } \right)\)	Best medicine
\({\mathcal{D}}_{H}\)	3.1986	2.9826	3.1060	2.8737	0.9014	2.7033	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{E}\)	1.0726	1.0525	1.1224	1.0175	0.4675	1.1000	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{nH}}}}\)	0.3998	0.3728	0.3884	0.3592	0.1127	0.3379	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{nE}}}}\)	0.3792	0.3721	0.3968	0.3597	0.1653	0.3889	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{BA}}}}^{1}\)	0.0776	0.0677	0.0790	0.0646	0.0136	0.0857	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{BA}}}}^{2}\)	0.2884	0.2546	0.2942	0.2626	0.0616	0.2750	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{G}\)	0.4000	0.3750	0.3625	0.3500	0.1125	0.3500	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{YF}}}}\)	0.4139	0.3834	0.3786	0.3603	0.1212	0.3522	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{WX}}}}\)	0.3531	0.3250	0.3344	0.3125	0.0938	0.3188	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{JHP}}}}\)	0.4069	0.3781	0.3834	0.3598	0.1169	0.3450	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{SF}}}}\)	0.1092	0.1135	0.0962	0.1178	0.0910	0.1635	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{RX}}}}\)	0.3955	0.3765	0.4287	0.3908	0.1884	0.4006	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{PY}}}}\)	0.4100	0.3687	0.4087	0.3825	0.1162	0.3312	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{EA}}}}\)	0.0241	0.0210	0.0218	0.0108	0.0005	0.0116	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{SB}}}}\)	0.4067	0.3721	0.4179	0.4025	0.1379	0.3467	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{MP}}}}\)	0.4410	0.3850	0.4506	0.4229	0.1156	0.3773	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{Chd}},1}}\)	0.3062	0.2912	0.2952	0.2683	0.0811	0.2559	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{Chd}},2}}\)	0.3280	0.3049	0.3089	0.2985	0.1246	0.2757	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{nAChd}},1}}^{0.3}\)	0.8572	0.8028	0.8544	0.8002	0.2824	0.7647	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{nAChd}},1}}^{0.8}\)	0.2942	0.2747	0.2902	0.2624	0.0748	0.2326	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{nAChd}},2}}^{0.3}\)	0.6470	0.6123	0.6379	0.5931	0.3246	0.5775	\(M_{5}\) (Tocilizumab)
\({\mathbf{\mathcal{D}}}_{{{\text{nAChd}},2}}^{0.8}\)	0.4128	0.3978	0.4015	0.3942	0.1671	0.3749	\(M_{5}\) (Tocilizumab)

Back to article page